valcyte在国内上市了没？

Has it been launched in China? Valcyte, branded as Valcyte, is an antiviral drug used to treat patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis, and to prevent CMV infection in high-risk solid organ transplant patients.

The recommended dose of valcyte for the treatment of induction of cytomegalovirus retinitis is 900 mg (two 450 mg tablets) twice daily for 21 days. Maintenance: After induction therapy, or in adult patients with inactive cytomegalovirus retinitis, the recommended dose is 900 mg orally once daily. Because valcyte is teratogenic, women should take a pregnancy test before initiating pregnancy and use effective contraception during treatment and for 30 days after treatment; men should use barrier contraception during treatment and for 90 days after treatment.

In May 2001, the US FDA approved the market. Valcyte is clinically used to treat acute retinitis caused by CMV infection in patients with acquired immunodeficiency syndrome. In May 2003, its indications were expanded. Valcyte is used to prevent and treat secondary CMV infection in organ transplant recipients. On August 11, 2010, Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) approved valcyte for the treatment of adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

  As early as 2006, valcyte has been successfully launched in my country. Patients can buy medicines in regular hospitals with prescriptions issued by doctors, but as the original drug, valganciclovir hydrochloride tablets are relatively expensive in China. According to the editor of Medical Companion Travel, Roche’s 450mg*60 tablets are sold in Indian pharmacies for about RMB 5,500. Since the exchange rate fluctuates and the price is not fixed, please consult Medical Travel for the specific price.